Alzheimer's Disease Trial, Not Yet Recruiting NCT07652931 Sponsor: IRCCS San Raffaele Condition: Alzheimer's Disease
Back to Alzheimers Disease

Alzheimer's Disease Trial, Not Yet Recruiting

NCT07652931
Not Yet Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who have been diagnosed with Subjective Cognitive Decline (SCD) — a condition where a person feels their memory or thinking has gotten worse compared to before, based on recognised international diagnostic guidelines.
  • People who have noticed a persistent decline in their own memory or thinking ability compared to how they used to be, which is not caused by a recent event or illness.
  • People whose performance on standard memory and thinking tests falls within the normal range for their age, gender, and education level (meaning they do not meet the criteria for mild cognitive impairment or early-stage Alzheimer's disease).
  • People aged 40 or older.
  • People whose native language is Italian.
  • People who have been on a stable medication routine for at least 4 weeks before joining the trial.
  • People who agree to participate and provide both spoken and written consent to take part in the study.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have already been diagnosed with mild cognitive impairment (MCI), early-stage Alzheimer's disease, or dementia.
  • People who have a significant ongoing condition affecting the body, mental health, or the brain or nervous system.
  • People with medical conditions or a history of substance misuse that could affect memory or thinking.
  • People who have a pacemaker or any other implanted device that stimulates the brain or nerves in the head or neck area.
  • People for whom having an MRI scan is not safe or suitable for any reason.
  • People whose routine MRI scan shows existing brain damage, including significant damage to blood vessels in the brain.
  • People with wounds from an injury or surgery in areas where the non-invasive brain stimulation device would be placed, due to infection risk.
  • People with skin or scalp conditions in the area where the device would be used that could cause abnormal levels of electrical current to pass through.
  • People with a known history of epilepsy, due to a small risk that the type of brain stimulation used in this trial (rTMS) could trigger a seizure in people with epilepsy.
  • People who do not agree to participate or who do not provide both spoken and written consent.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 7 August 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Massimo Filippi, Prof, IRCCS San Raffaele

Phone: 0226433051

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Sponsor
IRCCS San Raffaele
Registry
ClinicalTrials.gov
Start date
1 August 2026
Est. completion
1 August 2028

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Diagnostic accuracy of AI models in identifying AD biomarker-positive SCD subjects (AUC)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 7 August 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov